| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 21.77 | 8.7% | 19.9% |
| Total Income | 21.77 | 8.7% | 19.9% |
| Expenditure | 28.82 | 3.1% | 7.8% |
| PBT | — | ||
| Net Profit | -8.72 | 24.0% | 15.0% |
| OPM | -32.39% | 16.16pp | 14.94pp |
| NPM | -40.04% | 17.25pp | 16.48pp |
| EPS | -1.16 | 1350.0% | 1557.1% |
Biodesix Reports Q3 2025 Revenue of $21.8 Million, Up 20% YoY
04 May 2026 · 4 May, 8:21 am
Summary
Biodesix announced its Q3 2025 financial results, showcasing a 20% increase in revenue to $21.8 million. The gross profit margin improved to 81%, a 400-basis point increase year-over-year. Development Services revenue saw substantial growth, increasing by 97%. Based on the third quarter performance and ongoing momentum, the company is increasing its revenue guidance for 2025 to $84-86 million.
Key Highlights
- 1
Biodesix reported total revenue of $21.8 million for Q3 2025, representing a 20% increase compared to Q3 2024.
- 2
The company's gross profit margin for Q3 2025 was 81%, a 400-basis point improvement from Q3 2024.
- 3
Lung Diagnostic Testing revenue reached $19.8 million in Q3 2025, a 16% increase over the prior year.
- 4
Development Services revenue grew significantly by 97% to $1.9 million in Q3 2025 compared to the same period last year.
- 5
The company is increasing its 2025 revenue guidance and now expects to generate between $84 million and $86 million in total revenue.
- 6
Net loss improved by 15% to $8.7 million for Q3 2025 compared to the prior year.
- 7
Adjusted EBITDA loss improved by 18% to $4.6 million for Q3 2025 compared to the prior year.
Management Comments
Scott Hutton
We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year. Our strategic expansion into primary care is proving to be additive, demonstrating our ability to drive adoption in pulmonology while also partnering with them to drive upstream testing in their referral network. Additionally, our Development Services business continues to accelerate with 97% year-over-year growth and another quarter ending with a record number of dollars under contract. With our growing commercial organization and with the sustained positive momentum across both business units, we are well-positioned to achieve Adjusted EBITDA positivity in the fourth quarter. We believe the combination of our proven diagnostic solutions, expanding market reach, and operational excellence positions Biodesix for sustainable long-term growth as we continue to improve outcomes for patients with lung disease. Based on how we closed the third quarter and the ongoing momentum into the fourth quarter, we are increasing our revenue guidance for 2025 to $84-86 million.
Informational and educational content only. Not investment advice.